22 completed, 6 terminated, 3 withdrawn, 2 unknown. 20 Phase 2, 13 Phase 1, 4 Phase 3.
Follow lonafarnib: new trials by email Literature Review of lonafarnib trials Research Report on lonafarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) Progerinin, Lonafarnib - Hutchinson-Gilford Progeria Syndrome | Phase 2 | Completed | PRG Science & Technology Co., Ltd. | 10 | 2025-01-13 | 2026-10-02 |
| Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Lonafarnib, Ritonavir - Hepatitis D, Chronic | Phase 3 | Completed | Soroka University Medical Center | 10 | 2021-05-15 | 2026-04-30 |
| Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus | Phase 3 | Completed | Eiger BioPharmaceuticals | 407 | 2018-12-01 | 2023-04-14 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 26 | 2018-08-01 | 2021-12-14 |
| Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria Everolimus and lonafarnib - Progeria | Phase 1 / Phase 2 | Enrolling by invitation | Boston Children's Hospital | 80 | 2015-12-01 | 2026-04-02 |
| Titrating-Dose of Lonafarnib in Combination With Ritonavir lonafarnib, Ritonavir - Chronic Delta Hepatitis | Phase 2 | Completed | EIT Pharma, Inc. | 15 | 2015-09-01 | 2026-09-25 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Lonafarnib, Ritonavir, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 22 | 2015-07-29 | 2018-09-25 |
| Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) lonafarnib, ritonavir, Pegylated interferon-alfa-2a - Chronic Hepatitis D Infection | Phase 2 | Completed | EIT Pharma, Inc. | 55 | 2014-12-01 | 2026-09-25 |
| Lonafarnib With and Without Ritonavir in HDV (LOWR-1) lonafarnib, peginterferon alfa-2a, ritonavir - Chronic Hepatitis D Infection | Phase 2 | Completed | EIT Pharma, Inc. | 21 | 2014-11-01 | 2026-09-25 |
| Lonafarnib for Chronic Hepatitis D Lonafarnib, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 14 | 2011-12-01 | 2016-08-31 |
| Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, and Pravastatin - Progeria | Phase 2 | Unknown | Boston Children's Hospital | 85 | 2009-08-01 | 2023-02-27 |
| A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, Pravastatin - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Boston Children's Hospital | 5 | 2009-03-01 | 2019-06-13 |
| Lonafarnib in Metastatic Breast Cancer Lonafarnib - Metastatic Breast Cancer | Phase 2 | Terminated | George Sledge | 29 | 2008-10-01 | 2016-02-18 |
| A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) Docetaxel plus lonafarnib - Prostate Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | Merck Sharp & Dohme LLC | 5 | 2007-06-01 | 2015-02-05 |
| Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria Lonafarnib - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Monica E. Kleinman | 29 | 2007-05-01 | 2019-06-25 |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer Lonafarnib - Epithelial Ovarian Cancer | Phase 2 | Completed | AGO Study Group | 105 | 2006-01-01 | 2012-06-29 |
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer Lonafarnib, Docetaxel - Lung Cancer, Soft Tissue Sarcoma | Phase 1 | Terminated | Emory University | 38 | 2006-01-01 | 2012-12-18 |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Temodar and SCH 66336 - Gliosarcoma, Glioblastoma | Phase 1 | Completed | Duke University | 37 | 2005-10-01 | 2013-02-20 |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Lonafarnib, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 47 | 2005-05-01 | 2015-05-01 |
| 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC) Fenretinide (4-HPR), SCH66336 - Head and Neck Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2005-01-20 | 2018-11-15 |
Showing 20 of 36. Sign in to see all of them.
Progeria (6) · Breast Neoplasms (5) · Hepatitis D (5) · Glioblastoma (4) · Astrocytoma (3) · Brain Neoplasms (3) · Glioma (3) · Gliosarcoma (3) · Hepatitis D, Chronic (3) · Oligodendroglioma (3) · Central Nervous System Neoplasms (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Liver Diseases (2)
M.D. Anderson Cancer Center (7) · Merck Sharp & Dohme LLC (4) · Boston Children's Hospital (3) · EIT Pharma, Inc. (3) · Eiger BioPharmaceuticals (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · AGO Study Group (1) · Duke University (1) · Emory University (1) · George Sledge (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Monica E. Kleinman (1) · PRG Science & Technology Co., Ltd. (1)
United States (20) · Turkey (Türkiye) (4) · France (3) · Belgium (2) · Germany (2) · Israel (2) · Netherlands (2) · New Zealand (2) · Switzerland (2) · Bulgaria (1) · Canada (1) · Greece (1) · Italy (1) · Moldova (1) · Mongolia (1)
Cihan Yurdaydin, MD (2) · Mark W Kieran, MD, PhD (2) · Theo Heller, M.D. (2) · Annick Desjardins, MD (1) · Brian Leland-Jones, M.D. (1) · Christopher Koh, M.D. (1) · Eduardo B Martins, MD, DPhil (1) · Edward S Kim, MD (1) · George Sledge, M.D. (1) · Godefridus Peters, PhD (1) · Heiner Wedemeyer, MD, PhD (1) · Jan H. M. Schellens, MD, PhD (1) · John Kauh, MD (1) · Jorge Cortes, MD (1) · Jorge E. Cortes, MD (1)
PMID 24795390, PMID 27400896, PMID 30664876, PMID 36507973, PMID 36919608, PMID 15911238, PMID 17634493, PMID 22083160, PMID 22460337, PMID 22564713, PMID 22752073, PMID 23012407, PMID 23179651, PMID 23897869, PMID 24249802, PMID 26189433, PMID 34860418, PMID 37407002